Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis.
- Author:
Hwa Mi KIM
1
;
Seung Hun LEE
;
Chi Yeon KIM
Author Information
1. Department of Dermatology, School of Medicine, Gyeongsang National University, Jinju, Korea. cykim@gnu.ac.kr
- Publication Type:Case Report
- Keywords:
Epidermal growth factor receptor;
Erlotinib;
Radiation recall dermatitis
- MeSH:
Aged;
Carcinoma, Non-Small-Cell Lung;
Female;
Humans;
Lung Neoplasms;
Pancreatic Neoplasms;
Quinazolines;
Radiodermatitis;
Receptor, Epidermal Growth Factor;
Signal Transduction;
Erlotinib Hydrochloride
- From:Korean Journal of Dermatology
2010;48(10):872-875
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. A patient consulted our clinic and she had erythematous patches and vesicles on the submandibular area. She had taken erlotinib for the treatment of recurred lung cancer for 2 weeks. We report here on a case of radiation recall dermatitis that was induced by erlotinib in a 69-year-old woman who was previously irradiated on her submandibular area.
